CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

Rupesh Kotecha

CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

Rupesh Kotecha

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	22
State	Published - Jan 1 2020

Cite this

@article{65c567cfd99e42fca3eacc9622bc0b2b,

title = "CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)",

author = "Rupesh Kotecha",

note = "Neuro-Oncology (2020) 22(Supplement\_2):ii37-ii38",

year = "2020",

month = jan,

day = "1",

language = "American English",

volume = "22",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

AU - Kotecha, Rupesh

N1 - Neuro-Oncology (2020) 22(Supplement_2):ii37-ii38

PY - 2020/1/1

Y1 - 2020/1/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3946

M3 - Article

VL - 22

JO - Neuro-oncology

JF - Neuro-oncology

ER -

CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

Other files and links

Cite this